Thesis

Cassava Sciences will fail to meet the primary endpoint of their RethinkALZ Phase 3 study.

Premises

1. Whistleblower submission by the law firm Labaton Sucharow

Citizen petition Many Doctors signed

A lot of 2012 work is pinching on western bloods

One of the anti bodies that were ppurchased from santa cruz

NO SUITABLE ANTIBODIES WESTERN BLOTTING PAPER from 2007

1. Data Sheet from santa cruz for their antibody SC5544 Application shows something else. They were selling it for the purpose that SAVA used it for
2. THERE ARE NO SUITABLE
3. 2017 paper PMID 28763248 The researchers also confirmed that none of these antibodies is suitable for western blotting
4. Santa Cruz has discontinued the selling of this product
5. So what does the blotting showed if antibody is not able to detect a7etc
6. Sc65844 only detect a1 but they used it to detect a7
7. Elisabeth Bik(no financial interest in SAVA) taken a closer look out of professional curiosity For better science.com August 28 2021 western blotting is false
8. Second submission by Labaton Sucharow on November 21
9. SEC is investigating SAVA WSJ
10. Paper by Quintessential Capital November 3 2021

Extraordinary claims require extraordinary evidences

Characters of the story

Labaton Sucharow are representing two DR. David Bredt who joined MPM Capital before worked at Johnson and Johnson and Geoffery Pitt Prof at Cornel med school

Names of Researchers Dr Lindsay Burns, Remi Barbier (married to Burns), Hoau yan Wang